K118041P Anti-NCOA4 Polyclonal

Nuclear receptor coactivator 4 (NCOA4) also named androgen receptor (AR) coactivator ARA70， RFG and ELE1， is a putative co-activator that specifically enhances the activity of the androgen receptor. In human thyroid carcinomas， the Ret proto-oncogene fuses to ARA70 to form Ret/PTC3 by an intrachromosomal inversion of chromosome 10 in vivo. ARA70a can function as a ligand-enhanced co-activator of PPARg in adipocytes. However， PPARg-ARA70 transactivation can be squelched by AR， which suggests cross talk between PPARg- and AR-mediated response. ARA70a has no intrinsic transcription activation domain or histone acetyltransferase activity， but it interacts with histone acetyltransferase， p/CAF， CBP and p300/CBP-associated factors， and the basal transcription factor TFIIB. The interaction between ARA70 and AR occurs through the ligand-binding domain. The presence of ARA70 can enhance the androgenic activity of 17-b Estradiol (E2) and antiandrogens toward AR. ARA70 may be involved in prostate carcinogenesis and ovarian cancer and may serve as a key mediator of estrogen-androgen synergism.There are several isoforms of ZGPAT that are produced as a result of alternative splicing events. ARA70a is widely expressed， and its expression is highest in testis and adipose tissues， whereas ARA70b (The shorter variant， results from an internal 985-bp deletion.) is solely expressed in the testis.This antibody is a rabbit polyclonal antibody raised against the N-400aa of human NCOA4 protein.